Teva Pharmaceutical Industries Ltd. ADR

NYS: TEVA

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders

/marketstate/country/us

Teva Pharmaceutical Industries Ltd. ADR

Before the Bell

--Real time quotes

Feb 9, 2023, 7:36 a.m.

TEVA

/zigman2/quotes/205657894/composite

10.03

Change

+0.11 +1.11%

Volume

Volume 43,377

Real time quotes

/zigman2/quotes/205657894/composite

Previous close

$ 9.92

Change

-0.97 -8.91%

Day low

Day high

$9.90

$10.48

52 week low

52 week high

$6.78

$11.45

Income Statement Balance Sheet Cash Flow Statement

Annual Financials for Teva Pharmaceutical Industries Ltd. ADR

View Ratios

Fiscal year is January-December. All values ILS millions.	2017	2018	2019	2020	2021	5-year trend
Sales/Revenue	80.52B	65.69B	60.12B	57.29B	51.19B
Sales Growth	-	-18.42%	-8.48%	-4.70%	-10.65%
Cost of Goods Sold (COGS) incl. D&A	42.34B	35.86B	33.32B	30.72B	27.08B
COGS excluding D&A	34.87B	29.24B	27.18B	25.37B	22.78B
Depreciation & Amortization Expense	7.47B	6.62B	6.14B	5.35B	4.3B
Depreciation	2.27B	2.43B	2.17B	1.85B	1.71B
Amortization of Intangibles	5.19B	4.19B	3.97B	3.51B	2.59B
COGS Growth	-	-15.29%	-7.10%	-7.79%	-11.86%
Gross Income	38.18B	29.83B	26.8B	26.57B	24.11B
Gross Income Growth	-	-21.88%	-10.14%	-0.86%	-9.26%
Gross Profit Margin	-	-	-	-	47.10%	NA

	2017	2018	2019	2020	2021	5-year trend
SG&A Expense	23.83B	19.51B	17.16B	16.05B	14.2B
Research & Development	6.4B	4.36B	3.6B	3.43B	3.12B
Other SG&A	17.43B	15.15B	13.56B	12.62B	11.08B
SGA Growth	-	-18.11%	-12.05%	-6.45%	-11.55%
Other Operating Expense	-	-	-	-	-
Unusual Expense	81.2B	16.96B	11.1B	23.29B	4.35B
EBIT after Unusual Expense	(81.2B)	(16.96B)	(1.46B)	(12.78B)	5.56B
Non Operating Income/Expense	3.26B	553.67M	213.78M	137.56M	(187.35M)
Non-Operating Interest Income	302.15M	140.22M	146.08M	82.54M	-
Equity in Affiliates (Pretax)	-	-	-	-	-
Interest Expense	2.83B	3.38B	3.41B	2.6B	3.25B
Interest Expense Growth	-	19.38%	0.90%	-23.85%	25.15%
Gross Interest Expense	2.83B	3.38B	3.41B	2.6B	3.25B
Interest Capitalized	-	-	-	-	-
Pretax Income	(66.11B)	(9.33B)	(4.51B)	(15.15B)	2.13B
Pretax Income Growth	-	85.88%	51.71%	-236.18%	114.03%
Pretax Margin	-	-	-	-	4.15%	NA
Income Tax	(6.95B)	(701.08M)	(990.52M)	(577.76M)	681.56M
Income Tax - Current Domestic	1.34B	2.52B	3.15B	625.9M	872.13M
Income Tax - Current Foreign	-	-	-	-	-
Income Tax - Deferred Domestic	(8.29B)	(3.22B)	(4.14B)	(1.2B)	(190.58M)
Income Tax - Deferred Foreign	-	-	-	-	-
Income Tax Credits	-	-	-	-	-
Equity in Affiliates	(10.79M)	(255.26M)	(46.32M)	474.59M	29.07M
Other After Tax Income (Expense)	-	-	-	-	-
Consolidated Net Income	(59.17B)	(8.89B)	(3.56B)	(14.1B)	1.47B
Minority Interest Expense	(661.84M)	(1.16B)	(3.56M)	(378.29M)	125.97M
Net Income	(58.5B)	(7.73B)	(3.56B)	(13.72B)	1.35B
Net Income Growth	-	86.79%	53.95%	-285.50%	109.82%
Net Margin Growth	-	-	-	-	2.63%	NA
Extraordinaries & Discontinued Operations	-	-	-	-	-
Extra Items & Gain/Loss Sale Of Assets	-	-	-	-	-
Cumulative Effect - Accounting Chg	-	-	-	-	-
Discontinued Operations	-	-	-	-	-
Net Income After Extraordinaries	(58.5B)	(7.73B)	(3.56B)	(13.72B)	1.35B
Preferred Dividends	935.21M	895.22M	-	-	-
Net Income Available to Common	(59.44B)	(8.63B)	(3.56B)	(13.72B)	1.35B
EPS (Basic)	(58.50)	(8.45)	(3.26)	(12.53)	1.22
EPS (Basic) Growth	-	85.56%	61.38%	-284.10%	109.75%
Basic Shares Outstanding	1.02B	1.02B	1.09B	1.1B	1.1B
EPS (Diluted)	(58.50)	(8.45)	(3.26)	(12.53)	1.22
EPS (Diluted) Growth	-	85.56%	61.38%	-284.10%	109.71%
Diluted Shares Outstanding	1.02B	1.02B	1.09B	1.1B	1.11B
EBITDA	21.82B	16.94B	15.78B	15.87B	14.21B
EBITDA Growth	-	-22.39%	-6.85%	0.60%	-10.49%
EBITDA Margin	-	-	-	-	27.75%	NA

MarketWatch.com

Follow MarketWatch
RSS
Podcasts

Intraday Data provided by FACTSET and subject to terms of use. Historical and current end-of-day data provided by FACTSET. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.

Teva Pharmaceutical Industries Ltd. ADR

Annual Financials for Teva Pharmaceutical Industries Ltd. ADR

Latest News

dow

nasdaq

s&p 500

Kiosk